Neuraptive Announces Positive 24-Week Data for NTX-001 in the Phase 2 Study
Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
Neuraptive Announces Achievement of Proof of Concept in The Study of NTX-001
Neuraptive Therapeutics, Inc. Strengthens its Board of Directors With Appointment of Cary Sucoff, J.D.
PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board
PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.
PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI), today announced the enrollment of the first patient in its Phase 2a clinical trial evaluating the safety and efficacy of NTX-001 compared to the standard of care in the treatment and prevention of facial paralysis.
PHILADELPHIA--(BUSINESS WIRE)-- Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI), today announced the enrollment of the first patient in its Phase 2a clinical trial evaluating the safety and efficacy of NTX-001 compared to the standard of care in the treatment and prevention of facial paralysis.
PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs in the treatment of peripheral nerve injuries (PNI), today announced that the U.S. Food and Drug Administration (FDA) has cleared Neuraptive’s Investigational New Drug (IND) application for NTX-001 in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.